Home・Список акций・Omeros Corp

Omeros Corp

Закрыт

СекторЗдравоохранение

12.95 3.27

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

12.37

Макс.

13.04

Ключевые показатели
By Trading Economics
Доход	-35M 51M
Продажи	9.9M 9.9M
P/E Средняя по отрасли	11.018 68.51
Прибыль на акцию	0.57
Рентабельность продаж	518.033
Сотрудники	175
EBITDA	86M 57M

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+162.74% upside

Дивиденды
By Acuity
Следующий отчет о доходах	13 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-127M 909M
Предыдущая цена открытия	9.68
Предыдущая цена закрытия	12.95

Новостные настроения

By Acuity

46%

54%

167 / 340 Рейтинг в Healthcare

Omeros Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 23:02 UTC

Omeros Corp shares are lower in after-hours trading, reversing an initial gain despite strong recent performance above its 20-day moving average.

3 авг. 2026 г., 23:11 UTC

Event

Omeros Corp shares are lower in after-market trading following the CMS announcement on YARTEMLEA. The stock remains above its 20-day moving average.

1 авг. 2026 г., 00:01 UTC

Omeros Corp shares are higher in after-market trading, reaching a notable high and staying above the 20-day moving average. No specific news was identified.

31 июл. 2026 г., 23:41 UTC

Omeros Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

30 июл. 2026 г., 16:06 UTC

Omeros Corp shares are higher today, continuing a steady increase since Wednesday. The stock trades near the upper end of its one-month range.

29 июл. 2026 г., 18:58 UTC

Social Media

Omeros Corp is trading higher today, driven by positive social media sentiment despite broader weakness in the XBI sector. Market volume remains unusually high.

28 июл. 2026 г., 19:16 UTC

Social Media

Omeros Corp shares are lower today after earlier declines, amid social media discussions highlighting reduced competition following AstraZeneca's failed trial related to HSCT-TMA.

27 июл. 2026 г., 21:01 UTC

Omeros Corp shares are higher in after-market hours, following a broader market trend amid easing geopolitical tensions and declining oil prices.

24 июл. 2026 г., 19:26 UTC

Omeros Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the movement.

22 июл. 2026 г., 18:46 UTC

Omeros Corp shares are higher today, continuing an upward trend since Tuesday. Broader market dynamics are influenced by rising crude oil prices amid geopolitical tensions.

21 июл. 2026 г., 23:06 UTC

Omeros Corp. shares traded roughly flat in after-market hours. The stock remains below its 20-day moving average, marking three consecutive lower daily closes.

20 июл. 2026 г., 19:26 UTC

Omeros Corp shares are higher today, despite an earlier pullback. The stock has stabilized since Friday's close within its one-month trading range.

Сравнение c конкурентами

Изменение цены

Omeros Corp Прогноз

Целевая цена

By TipRanks

162.74% рост

Прогноз на 12 месяцев

Средняя 33 USD 162.74%

Максимум 33 USD

Минимум 33 USD

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Omeros Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

2 ratings

Покупка

Удержание

Продажа

Основано на мнении 2 аналитиков, присваивавших рейтинги акциям Omeros Corp – Данные за последние 3 месяца.

Настроения

By Acuity

167 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.